Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185".

Letter to the editor / Critical review of existing literature regarding BPC 157

“We wish to thank the Authors of the comment for their interest in our manuscript [1].”

BPC 157 peptide (and references to rat, dog, mouse, and human studies)

“We understand and respect that they defend the peptide they have worked on for many years.”

The majority of available studies on BPC 157 originate from a single research center, limiting generalizability and increasing the risk of confirmation bias.

“Heavy reliance on self-replication inevitably restricts generalizability and increases the risk of confirmation bias.”

No published in vivo data demonstrate that BPC 157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis.

“To date, no published in vivo data demonstrate that BPC 157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis.”